Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Industry News
New R&D Agreement for Anticancer Research Announced
May 26th, 1997
Bristol-Myers Squibb Company, Princeton, New Jersey, and Research Triangle Institute, Research Triangle Park, North Carolina, announced that they have entered into a research and licensing agreement to develop synthetic third-generation analogs of naturally occurring plant alkaloid compounds known as camptothecins, which are known to have unique cancer-fighting properties. Researchers at Bristol-Myers Squibb and Research Triangle Institute (RTI) believe that these camptothecin analogs have the potential to become efficacious chemotherapeutic agents. According to the terms of the agreement, Bristol-Myers Squibb will fund a three-year research program...
Source: Cancer Weekly (1997-05-26)
|
